摘要
肺癌靶向药物的应用显著改善了患者的预后,但几乎所有靶向药物在治疗过程中会出现继发耐药。本文对肺癌靶向治疗研究进展及耐药处理方案进行综述,为临床药物治疗提供参考。
The application of targeted drugs has significantly improved the prognosis of patients with lung cancer,but almost all targeted drugs will develop secondary resistance during treatment.This article reviews the progress of lung cancer targeted therapy and drug resistance treatment scheme,and provides reference for lung cancer treatment.
作者
朱愿超
胡欣
艾斌
ZHU Yuan-chao;HU Xin;AI Bin(Department of Pharmacy,Beijing Hospital/National Center of Gerontology,Beijing 100730,China;Assessment of Clinical Drugs Risk and Individual Application Key Laboratory,Beijing Hospital/National Center of Gerontology,Beijing 100730,China;Department of Oncology,Beijing Hospital/National Center of Gerontology,Beijing 100730,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2019年第17期1951-1955,共5页
The Chinese Journal of Clinical Pharmacology
关键词
非小细胞肺癌
表皮生长因子受体抑制药
间变性淋巴瘤激酶酪氨酸激酶抑制药
耐药
non-small cell lung cancer
epidermal growth factor receptor inhibitor
anaplastic lymphoma kinase tyrosine kinase inhibitor
drug resistance
